A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications

References

• BajajMSuraamornkulSPratipanawatrTPioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetesDiabetes20035213647012765945
   PubMed Web of Science ®Google Scholar
• BerhanuPKipnesMSKhanMAEffects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy.Diabetes and Vascular Disease Research200633944 [erratum appears in Diab Vasc Dis Res. 2006; 3(2):71]16784180
   PubMedGoogle Scholar
• BodlesAMVarmaVYao-BorengasserAPioglitazone induces apoptosis of macrophages in human adipose tissueJournal of Lipid Research2006M600235MJLR200
   Web of Science ®Google Scholar
• Bonnefont-RousselotDRajiBWalrandSAn intracellular modulation of free radical production could contribute to the beneficial effects of metformin towards oxidative stressMetabolism: Clinical and Experimental200352586912759888
   PubMed Web of Science ®Google Scholar
• [CDC] Centers for Disease Control and PreventionDiabetes data and trends [online]2006 URL: http://www.cdc.gov/diabetes/statistics
   Google Scholar
• ChenMNagaseMFujitaTDiabetes enhances lectin-like oxidized LDL receptor-1 (LOX-1) expression in the vascular endothelium: possible role of LOX-1 ligand and AGEBiochemical and Biophysical Research Communications2001287962811573959
   PubMed Web of Science ®Google Scholar
• ChengAYFantusIGThiazolidinedione-induced congestive heart failureAnnals of Pharmacotherapy2004388172015039476
   PubMed Web of Science ®Google Scholar
• ChiuHCKovacsAFordDAA novel mouse model of lipotoxic cardiomyopathyJournal of Clinical Investigation20011078132211285300
   PubMed Web of Science ®Google Scholar
• ChuNVKongAPSKimDDDifferential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetesDiabetes Care200225542911874944
   PubMed Web of Science ®Google Scholar
• CusiKConsoliADeFronzoRAMetabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitusJournal of Clinical Endocrinology Metabolism1996814059678923861
   PubMed Web of Science ®Google Scholar
• DavignonJGanzPRole of endothelial dysfunction in atherosclerosisCirculation200410923 Suppl 1III273215198963
   PubMed Web of Science ®Google Scholar
• DeJJKooyALehertPEffects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized,placebo-controlled trialJournal of Internal Medicine2005257100915606381
   PubMed Web of Science ®Google Scholar
• DeFronzoRABarzilaiNSimonsonDCMechanism of metformin action in obese and lean noninsulin-dependent diabetic subjectsJournal of Clinical Endocrinology and Metabolism19917312943011955512
   PubMed Web of Science ®Google Scholar
• Di BonitoPCuomoSMoioNDiastolic dysfunction in patients with non-insulin-dependent diabetes mellitus of short durationDiabetic Medicine19961332149162606
   PubMed Web of Science ®Google Scholar
• Di GregorioGBYao-BorengasserARasouliNExpression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazoneDiabetes20055423051316046295
   PubMed Web of Science ®Google Scholar
• DorellaMGiustoMDaTVImprovement of insulin sensitivity by metformin treatment does not lower blood pressure of nonobese insulin-resistant hypertensive patients with normal glucose toleranceJournal of Clinical Endocrinology and Metabolism1996811568748636369
   PubMed Web of Science ®Google Scholar
• DormandyJACharbonnelBEcklandDJSecondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialLancet200536612798916214598
   PubMed Web of Science ®Google Scholar
• EurichDTMajumdarSRMcAlisterFAImproved clinical outcomes associated with metformin in patients with diabetes and heart failureDiabetes Care20052823455116186261
   PubMed Web of Science ®Google Scholar
• FriedmanJFat in all the wrong placesNature2002415268911796987
   PubMed Web of Science ®Google Scholar
• GalassiAReynoldsKHeJMetabolic syndrome and risk of cardiovascular disease: a meta-analysisThe American Journal of Medicine20061198121917000207
   PubMed Web of Science ®Google Scholar
• GuntonJEDelhantyPJDTakahashiSIMetformin rapidly increases insulin receptor activation in human liver and signals preferentially through insulin-receptor substrate-2Journal of Clinical Endocrinology Metabolism20038813233212629126
   PubMed Web of Science ®Google Scholar
• HotamisligilGSRole of endoplasmic reticulum stress and c-Jun NH2-terminal kinase pathways in inflammation and origin of obesity and diabetesDiabetes200554Suppl 2S73816306344
   PubMed Web of Science ®Google Scholar
• HoustisNRosenEDLanderESReactive oxygen species have a causal role in multiple forms of insulin resistanceNature2006440944816612386
   PubMed Web of Science ®Google Scholar
• HwangJKleinhenzDJRupnowHLThe PPARgamma ligand, rosiglitazone, reduces vascular oxidative stress and NADPH oxidase expression in diabetic miceVascular Pharmacology2007464566217337254
   PubMed Web of Science ®Google Scholar
• ImamotoEYoshidaNUchiyamaKInhibitory effect of pioglitazone on expression of adhesion molecules on neutrophils and endothelial cellsBiofactors192013747
   Google Scholar
• JohnsonJASimpsonSHTothELReduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetesDiabetic Medicine20052249750215787679
   PubMed Web of Science ®Google Scholar
• KermaniAGargAThiazolidinedione-associated congestive heart failure and pulmonary edemaMayo Clinic Proceedings20037810889112962163
   PubMed Web of Science ®Google Scholar
• KimSKZhaoZSLeeYJLeft-ventricular diastolic dysfunction may be prevented by chronic treatment with PPAR-alpha or -gamma agonists in a type 2 diabetic animal modelDiabetes/Metabolism Research Reviews20031948793
   PubMed Web of Science ®Google Scholar
• KimYBCiaraldiTPKongATroglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjectsDiabetes200251443811812753
   PubMed Web of Science ®Google Scholar
• KongJYRabkinSWPalmitate-induced apoptosis in cardiomyocytes is mediated through alterations in mitochondria: prevention by cyclosporin ABiochimica et Biophysica Acta20001485455510802248
   PubMed Web of Science ®Google Scholar
• LiCLPanCYLuJMEffect of metformin on patients with impaired glucose toleranceDiabetic Medicine1999164778110391395
   PubMed Web of Science ®Google Scholar
• LiDLiuLChenHLOX-1, an oxidized LDL endothelial receptor, induces CD40/CD40L signaling in human coronary artery endothelial cellsArteriosclerosis, Thrombosis and Vascular Biology20032381621
   PubMed Web of Science ®Google Scholar
• LiDMehtaJLAntisense to LOX-1 inhibits oxidized LDL-mediated upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cellsCirculation200010128899510869259
   PubMed Web of Science ®Google Scholar
• LiLMamputuJCWiernspergerNSignaling pathways involved in human vascular smooth muscle cell proliferation and matrix metalloproteinase-2 expression induced by leptin: inhibitory effect of metforminDiabetes20055422273415983226
   PubMed Web of Science ®Google Scholar
• MadamanchiNRRungeMSMitochondrial dysfunction in atherosclerosisCirculation Research20071004607317332437
   PubMed Web of Science ®Google Scholar
• MahroufMOuslimaniNPeynetJMetformin reduces angiotensin-mediated intracellular production of reactive oxygen species in endothelial cells through the inhibition of protein kinase CBiochemical Pharmacology2006721768316730666
   PubMed Web of Science ®Google Scholar
• MartensFMVisserenFLde KoningEJShort-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetesJournal of Cardiovascular Pharmacology200546773816306801
   PubMed Web of Science ®Google Scholar
• MartinBCWarramJHKrolewskiASRole of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up studyLancet199234092591357346
   PubMed Web of Science ®Google Scholar
• Mathieu-CostelloOKongACiaraldiTPRegulation of skeletal muscle morphology in type 2 diabetic subjects by troglitazone and metformin: relationship to glucose disposalMetabolism200352540612759881
   PubMed Web of Science ®Google Scholar
• MehtaJLHuBChenJPioglitazone inhibits LOX-1 expression in human coronary artery endothelial cells by reducing intracellular superoxide radical generationArteriosclerosis, Thrombosis and Vascular Biology20032322038
   PubMed Web of Science ®Google Scholar
• MehtaJLRasouliNSinhaAKOxidative stress in diabetes: A mechanistic overview of its effects on atherogenesis and myocardial dysfunctionThe International Journal of Biochemistry and Cell Biology200638794803
   PubMed Web of Science ®Google Scholar
• MoghettiPCastelloRNegriCMetformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluationJournal of Clinical Endocrinology and Metabolism2000851394610634377
   PubMed Web of Science ®Google Scholar
• MorelYGolayAPernegerTMetformin treatment leads to an increase in basal, but not insulin-stimulated, glucose disposal in obese patients with impaired glucose toleranceDiabetic Medicine199916650510477209
   PubMed Web of Science ®Google Scholar
• NishikawaTEdelsteinDDuXLNormalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damageNature20004047879010783895
   PubMed Web of Science ®Google Scholar
• NitenbergAValensiPSachsRImpairment of coronary vascular reserve and ACh-induced coronary vasodilation in diabetic patients with angiographically normal coronary arteries and normal left ventricular systolic functionDiabetes1993421017258513969
   PubMed Web of Science ®Google Scholar
• NolanJJLudvikBBeerdsenPImprovement in glucose tolerance and insulin resistance in obese subjects treated with troglitazoneNew England Journal of Medicine19943311188937935656
   PubMed Web of Science ®Google Scholar
• OuslimaniNPeynetJBonnefont-RousselotDMetformin decreases intracellular production of reactive oxygen species in aortic endothelial cellsMetabolism: Clinical and Experimental2005548293415931622
   PubMed Web of Science ®Google Scholar
• PambiancoGCostacouTEllisDThe 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experienceDiabetes2006551463916644706
   PubMed Web of Science ®Google Scholar
• PerseghinGScifoPDe CobelliFIntramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1H–13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parentsDiabetes1999481600610426379
   PubMed Web of Science ®Google Scholar
• PetersenKFDufourSBefroyDImpaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetesThe New England Journal of Medicine20043506647114960743
   PubMed Web of Science ®Google Scholar
• RasouliNRaueUMilesLMPioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissueAJP – Endocrinology and Metabolism2005288E9304
   Web of Science ®Google Scholar
• RasouliNYao-BorengasserAMilesLMIncreased plasma adiponectin in response to pioglitazone does not result from increased gene expressionAJP – Endocrinology and Metabolism2006290E426
   Web of Science ®Google Scholar
• Rodriguez-ManasLLopez-DorigaPPetidierREffect of glycaemic control on the vascular nitric oxide system in patients with type 1 diabetes [see comment]Journal of Hypertension20032111374312777950
   PubMed Web of Science ®Google Scholar
• RosenPWiernspergerNFMetformin delays the manifestation of diabetes and vascular dysfunction in Goto-Kakizaki rats by reduction of mitochondrial oxidative stressDiabetes/Metabolism Research Reviews20062232330
   PubMed Web of Science ®Google Scholar
• RublerSDlugashJYuceogluYZNew type of cardiomyopathy associated with diabetic glomerulosclerosisAmerican Journal of Cardiology1972305956024263660
   PubMed Web of Science ®Google Scholar
• Saenz de TejadaIGoldsteinIAzadzoiKImpaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotenceNew England Journal of Medicine19893201025302927481
   PubMed Web of Science ®Google Scholar
• SchrauwenPHesselinkMKOxidative capacity, lipotoxicity, and mitochondrial damage in type 2 diabetesDiabetes20045314121715161742
   PubMed Web of Science ®Google Scholar
• StumvollMNurjhanNPerrielloGMetabolic effects of metformin in non-insulin-dependent diabetes mellitusNew England Journal of Medicine199533355047623903
   PubMed Web of Science ®Google Scholar
• SuwaMEgashiraTNakanoHMetformin increases the PGC-1{alpha} protein and oxidative enzyme activities possibly via AMPK phosphorylation in skeletal muscle in vivoJournal of Applied Physiology200610116859216902066
   PubMed Web of Science ®Google Scholar
• SzaparyPOBloedonLTSamahaFFEffects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndromeArteriosclerosis, Thrombosis and Vascular Biology2006261828
   PubMed Web of Science ®Google Scholar
• The Diabetes Prevention Program Research GroupIntensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose toleranceDiabetes20055415667215855347
   PubMed Web of Science ®Google Scholar
• TziakasDNChalikiasGKKaskiJCEpidemiology of the diabetic heartCoronary Artery Disease200516Suppl 1S31016340402
   PubMedGoogle Scholar
• UngerRHMinireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndromeEndocrinology200314451596512960011
   PubMed Web of Science ®Google Scholar
• VelazquezEMMendozaSHamerTMetformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancyMetabolism: Clinical and Experimental199443647548177055
   PubMed Web of Science ®Google Scholar
• VincentHKTaylorAGBiomarkers and potential mechanisms of obesity-induced oxidant stress in humansInternational Journal of Obesity2006304001816302012
   PubMed Web of Science ®Google Scholar
• WidenEIErikssonJGGroopLCMetformin normalizes nonoxidative glucose metabolism in insulin-resistant normoglycemic first-degree relatives of patients with NIDDMDiabetes19924135481551495
   PubMed Web of Science ®Google Scholar
• Yki-JarvinenHThiazolidinedionesThe New England Journal of Medicine200435111061815356308
   PubMed Web of Science ®Google Scholar
• ZhouGMyersRLiYRole of AMP-activated protein kinase in mechanism of metformin actionJ Clin Invest200110811677411602624
   PubMed Web of Science ®Google Scholar
• ZhouYTGrayburnPKarimALipotoxic heart disease in obese rats: implications for human obesityProceedings of the National Academy of Sciences of the United States of America2000971784910677535
   PubMed Web of Science ®Google Scholar